NanoSyrinx is developing a synthetic biology platform for the targeted intracellular delivery of biologic drugs, such as antibodies and peptides, which often struggle with bioavailability. By utilizing a novel "nanosyringe" technology, the company aims to enhance the effectiveness of these therapies by ensuring precise delivery to specific cells.
Funding
$20.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BGFounders
Product
Problem
Many biologic drugs, including antibodies and peptides, face significant challenges in effectively traversing the body and reaching intracellular targets, limiting their therapeutic potential. This bioavailability issue hinders the development of effective treatments for previously "undruggable" intracellular targets.
Solution
NanoSyrinx is developing a synthetic biology platform that utilizes engineered "nanosyringes" for targeted intracellular delivery of biologic molecules. This technology enables selective and direct delivery of peptide and protein payloads, including gene editors and enzymes, into the cytosol of targeted cells. By overcoming the limitations of traditional drug delivery methods, NanoSyrinx aims to enhance the effectiveness of biologic therapeutics and unlock new intervention possibilities for unmet medical needs. The platform is based on naturally occurring nanosyringes, which are modified to transport complex biologic payloads.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing biologic therapeutics, particularly those targeting intracellular processes.
Features
- Engineered nanosyringes for targeted delivery of biologics
- Selective and direct delivery of payloads into the cell cytosol
- Delivery of diverse biologic molecules, including peptides, proteins, gene editors, and enzymes
- Potential to address previously "undruggable" intracellular targets